NCT05392764

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Empagliflozin in Patients With Acute Heart Failure

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 444 (estimated)
• Sponsor: Juntendo University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.

Conditions

• Acute Heart Failure

Interventions

Type	Name	Description
DRUG	Empagliflozin 10 MG	once-daily oral empagliflozin 10 mg
DRUG	Placebo	Placebo matching empagliflozin 10 mg

Timeline

• Start date: 2022-09-10
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2022-05-26
• Last updated: 2026-02-13

Locations

69 sites across 1 country: Japan